Cognitive Neurology Clinics Are Operating at the Edge of Capacity
The United States is in the early stages of a dementia care crisis. The Alzheimer's Association projects that the number of Americans living with Alzheimer's disease will grow from approximately 6.9 million in 2024 to nearly 13 million by 2050. Memory disorder clinics and cognitive neurology practices serve as the front line for diagnosis — and they are understaffed, under-resourced, and drowning in administrative complexity.
A typical new patient workup for cognitive impairment involves neuropsychological testing, advanced neuroimaging including amyloid or FDG-PET scans, laboratory evaluation, and specialist referrals. The diagnostic process may span months and requires coordinated documentation across multiple providers, insurance payers, and testing facilities. Meanwhile, the emergence of FDA-approved anti-amyloid therapies such as lecanemab (Leqembi) and donanemab has added a new administrative dimension: clinical trial screening and enrollment coordination.
Neuropsychological Testing Scheduling: Managing Long Waitlists and Documentation Requirements
Neuropsychological evaluation is the cornerstone of dementia workup — and one of the hardest services to access promptly. Neuropsychology practices often have waitlists of three to six months, and many require referring providers to submit specific documentation: cognitive screening scores (MoCA, MMSE), medication lists, educational history, and primary language designation.
A virtual assistant can dramatically smooth this process. The VA gathers required intake documentation at the time of referral, submits it to the neuropsychology office in the format required, tracks waitlist position, communicates wait-time expectations to patients and families, and confirms appointments once scheduled. When a neuropsychology practice has an earlier cancellation slot, the VA fields the call and expedites the rescheduling — something a busy clinic nurse rarely has bandwidth to do proactively.
PET Scan Referral Coordination: Amyloid and FDG-PET Logistics
Amyloid PET scanning (using tracers such as florbetapir/Amyvid, florbetaben/Neuraceq, or flutemetamol/Vizamyl) and FDG-PET for differential diagnosis of neurodegenerative syndromes require insurance pre-authorization, appropriate CMS coverage criteria documentation (for Medicare patients), and coordination with nuclear medicine facilities that may not be co-located with the memory clinic.
A VA manages the PET referral pipeline: verifying that the patient meets CMS or commercial payer coverage criteria, preparing prior authorization packages with cognitive testing results and clinical notes, identifying facilities with available imaging slots, coordinating transport for patients who cannot drive independently, and following up to confirm that scan results have been received and routed to the ordering neurologist before the next scheduled visit.
Clinical Trial Eligibility Screening Support
With the approval of anti-amyloid therapies and a robust pipeline of Alzheimer's disease clinical trials, cognitive neurology clinics are increasingly being approached to refer or enroll patients. Prescreening patients for eligibility — based on age, cognitive stage (MCI vs. mild dementia), amyloid biomarker status, absence of exclusion criteria — is time-consuming but essential for research participation.
A VA can support prescreening by reviewing upcoming patients against published trial inclusion/exclusion criteria, preparing a structured summary for the neurologist review, contacting the research coordinator with candidate referrals, and managing the consent scheduling logistics. According to the Alzheimer's Clinical Trials Consortium (ACTC), administrative bottlenecks are among the top three reasons eligible patients are not enrolled in prevention trials.
Caregiver Education Resource Coordination
Caregivers of patients with dementia bear an enormous burden, and memory disorder clinics are increasingly expected to support them as part of comprehensive care. Directing caregivers to the Alzheimer's Association's 24/7 helpline, local support groups, respite care resources, and advance care planning tools requires coordination that most clinical teams lack time to provide consistently.
A VA can build and maintain a standardized caregiver resource packet, send it automatically after new dementia diagnosis visits, follow up with caregivers at 30 and 90 days to check resource engagement, and flag signs of caregiver distress for clinical team follow-up.
Memory disorder clinics seeking to expand their administrative capacity can partner with trained healthcare VAs through Stealth Agents.
Sources
- Alzheimer's Association. "2024 Alzheimer's Disease Facts and Figures." Alz.org, 2024.
- Alzheimer's Clinical Trials Consortium. "Barriers to Enrollment in Alzheimer's Prevention Trials." ACTC.org, 2023.
- Centers for Medicare & Medicaid Services. "CMS Coverage of Beta-Amyloid PET Scans in Dementia." CMS.gov, 2023.
- Journal of Alzheimer's Disease. "Neuropsychological Evaluation Waitlist and Diagnostic Delay." JAD, 2022; 85(2): 601–610.